These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 37864424)

  • 1. A narrative review of non-racemic amisulpride (SEP-4199) for treatment of depressive symptoms in bipolar disorder and LB-102 for treatment of schizophrenia.
    Wu J; Kwan AT; Rhee TG; Ho R; d'Andrea G; Martinotti G; Teopiz KM; Ceban F; McIntyre RS
    Expert Rev Clin Pharmacol; 2023; 16(11):1085-1092. PubMed ID: 37864424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of Nonracemic Amisulpride to Maximize Benefit/Risk of 5-HT7 and D2 Receptor Antagonism for the Treatment of Mood Disorders.
    Hopkins SC; Wilkinson S; Corriveau TJ; Nishikawa H; Nakamichi K; Loebel A; Koblan KS
    Clin Pharmacol Ther; 2021 Sep; 110(3):808-815. PubMed ID: 33961287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy of atypical antipsychotics in depressive syndromes].
    Quintin P; Thomas P
    Encephale; 2004; 30(6):583-9. PubMed ID: 15738862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Randomized, Double-blind, Placebo-controlled Proof-of-Concept Trial to Evaluate the Efficacy and Safety of Non-racemic Amisulpride (SEP-4199) for the Treatment of Bipolar I Depression.
    Loebel A; Koblan KS; Tsai J; Deng L; Fava M; Kent J; Hopkins SC
    J Affect Disord; 2022 Jan; 296():549-558. PubMed ID: 34614447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amisulpride: a review of its use in the management of schizophrenia.
    Curran MP; Perry CM
    Drugs; 2001; 61(14):2123-50. PubMed ID: 11735643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of amisulpride for depressive symptoms in individuals with mental disorders: A systematic review and meta-analysis.
    Zangani C; Giordano B; Stein HC; Bonora S; D'Agostino A; Ostinelli EG
    Hum Psychopharmacol; 2021 Nov; 36(6):e2801. PubMed ID: 34727399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amisulpride-induced mania in a patient with schizophrenia.
    Murphy BP
    Br J Psychiatry; 2003 Aug; 183():172. PubMed ID: 12893676
    [No Abstract]   [Full Text] [Related]  

  • 8. [Antipsychotics in bipolar disorders].
    Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
    Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amisulpride a selective dopamine antagonist and atypical antipsychotic: results of a meta-analysis of randomized controlled trials.
    Leucht S
    Int J Neuropsychopharmacol; 2004 Mar; 7 Suppl 1():S15-20. PubMed ID: 14972080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maximizing response to first-line antipsychotics in schizophrenia: a review focused on finding from meta-analysis.
    Smith RC; Leucht S; Davis JM
    Psychopharmacology (Berl); 2019 Feb; 236(2):545-559. PubMed ID: 30506237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical update on amisulpride in deficit schizophrenia.
    Rein W; Turjanski S
    Int Clin Psychopharmacol; 1997 May; 12 Suppl 2():S19-27. PubMed ID: 9218164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An open-label study of amisulpride in the treatment of mania.
    Vieta E; Ros S; Goikolea JM; Benabarre A; Popova E; Comes M; Capapey J; Sánchez-Moreno J
    J Clin Psychiatry; 2005 May; 66(5):575-8. PubMed ID: 15889942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amisulpride for schizophrenia.
    Mota NE; Lima MS; Soares BG
    Cochrane Database Syst Rev; 2002; 2002(2):CD001357. PubMed ID: 12076408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Striatal D2/D3 receptor occupancy, clinical response and side effects with amisulpride: an iodine-123-iodobenzamide SPET study.
    Meisenzahl EM; Schmitt G; Gründer G; Dresel S; Frodl T; la Fougère C; Scheuerecker J; Schwarz M; Boerner R; Stauss J; Hahn K; Möller HJ
    Pharmacopsychiatry; 2008 Sep; 41(5):169-75. PubMed ID: 18763218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is amisulpride an 'atypical' atypical antipsychotic agent?
    Lecrubier Y
    Int Clin Psychopharmacol; 2000 Dec; 15 Suppl 4():S21-6. PubMed ID: 11252520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spotlight on amisulpride in schizophrenia.
    Curran MP; Perry CM
    CNS Drugs; 2002; 16(3):207-11. PubMed ID: 11888341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of negative symptoms in schizophrenia by amisulpride. Review of the literature].
    Pélissolo A; Krebs MO; Olié JP
    Encephale; 1996; 22(3):215-9. PubMed ID: 8767050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Focus on amisulpride.
    Green B
    Curr Med Res Opin; 2002; 18(3):113-7. PubMed ID: 12094819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of negative symptoms in schizophrenia with amisulpride.
    Boyer P; Lecrubier Y; Puech AJ; Dewailly J; Aubin F
    Br J Psychiatry; 1995 Jan; 166(1):68-72. PubMed ID: 7894879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second-generation antipsychotics for major depressive disorder and dysthymia.
    Komossa K; Depping AM; Gaudchau A; Kissling W; Leucht S
    Cochrane Database Syst Rev; 2010 Dec; (12):CD008121. PubMed ID: 21154393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.